AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02767089 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone
Description: Subjects will receive oral prednisone and/or placebo tablets (total of 4 tablets) to achieve the required dose according to the treatment sequence group they were randomized. Subjects are to be dosed each morning for 7 days. A 14 day washout period is required between each period. Prednisone was supplied in the 2.5 and 20 mg dosage strengths.
Study NCT02767089 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo tablets similar to Prednisone 2.5 mg and 20 mg were supplied to make the trial doses.
Study NCT03636997 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Draining seton
Description: Number 1 silk suture was passed through the fistula track and tied as loose seton
Study NCT03636997 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rerouting of track
Description: The seton and fistula track were rerouted to involve the internal anal sphicnter only and spare the external sphincter
Study NCT01233895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE1642
Description: For Part 1, AVE1642 was administered on Day 1 and then every three weeks intra-venously with the dose escalation step starting at 3 mg/kg/infusion with a classical dose escalation schema of 3+3. For Part 2, AVE1642 was administered at doses ranging from 0.5 mg/kg to 12 mg/kg
Study NCT01233895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: For Part 2 ONLY, fixed dose of 1.3 mg/m² administered on Days 1, 4, 8, and 11.
Study NCT02834013 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT02834013 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT02834013 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT03023410 — intervention group
Intervention type: PROCEDURE
Intervention: VERASENSE
Description: Sensor-Assisted Revision TKA
Study NCT03418038 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Given IV
Study NCT03418038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV or PO
Study NCT03418038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV or PO
Study NCT03418038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV or PO
Study NCT03418038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV or PO
Study NCT02834013 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT02834013 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT02834013 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT04159870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin pills 400 mg x 3/day
Study NCT04159870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norfloxacin
Description: Norlfloxacin 400 mg 1 pill/day
Study NCT01823835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0810
Description: GDC-0810 administered orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years).
Study NCT01823835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH Agonist
Description: LHRH agonist administered once monthly until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years). Choice of LHRH agonist will be an institutional choice approved for use in breast cancer.
Study NCT01823835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib administered orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years).
Study NCT04774848 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Frequency Jet Ventilator
Description: HFJV provides short bursts of gas into the respiratory circuit at a rate of 240 to 600/min (4 to 11 Hz) and expiration is passive. It is used in conjunction with a conventional ventilator which provides positive end expiratory pressure (PEEP) and can also provide occasional sigh breaths.
Study NCT03418038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV or PO
Study NCT03418038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IV or PO
Study NCT03418038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV or PO
Study NCT03418038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given IV or PO
Study NCT03418038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV or PO
Study NCT03418038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV or PO
Study NCT03418038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV or PO
Study NCT03418038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV or PO
Study NCT03418038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide
Description: Given IV or PO
Study NCT03418038 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03418038 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03418038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV or PO
Study NCT03418038 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given normal saline IV
Study NCT03418038 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03418038 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03418038 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT03418038 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Given IV
Study NCT03418038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV
Study NCT03418038 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT03418038 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT03418038 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Core Biopsy
Description: Undergo core needle biopsy
Study NCT03418038 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Core Biopsy
Description: Undergo core needle biopsy
Study NCT03418038 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration and biopsy
Study NCT01675271 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: individual exercise
Description: individual exercise and dietary prescription
Study NCT01675271 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: general exercise
Description: general exercise counselling
Study NCT03440021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741
Description: Novel selective alpha2c adrenoceptor antagonist
Study NCT03440021 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical in appearance to experimental drug, not psycho-active
Study NCT02373215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine HCL ER
Description: Nalbuphine HCL extended release tablet
Study NCT03418038 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration and biopsy
Study NCT03418038 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspiration and biopsy
Study NCT03418038 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspiration and biopsy
Study NCT01140997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ypeginterferon alfa-2b
Description: sc, qw, for 48 weeks.
Study NCT01140997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: sc, qw, for 48 weeks.
Study NCT03418038 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT03418038 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT03418038 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT03418038 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT03418038 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03418038 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03418038 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Central Venous Cannula Insertion
Description: Undergo PICC placement
Study NCT03418038 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Portacath Placement
Description: Undergo portacath placement
Study NCT03418038 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT
Study NCT03418038 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo PET/CT
Study NCT04690348 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Craniotomy
Description: Craniotomy
Study NCT04690348 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Craniotomy
Description: Craniotomy
Study NCT04690348 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cesium-131 brachytherapy
Description: Intracavitary Cesium-131 brachytherapy
Study NCT03974178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexinidazole
Description: Tablets of 600 mg; Participants with a weight between 20 and 34 kg received 1200 mg (2 tablets) for 4 days, then 600 mg (1 tablet) for 6 days (with food); Participants with a weight of 35 kg and above received 1800 mg (3 tablets) for 4 days, then 1200 mg (2 tablets) for 6 days (with food)
Study NCT05650788 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: NMR spectrometry
Description: The MRI protocol will be carried out at 3 Tesla (3T) on a Siemens NMR imaging system (Magnetom Vida, Siemens Healthcare, Erlangen, Germany), the emission of radiofrequency waves and the reception of the signal will be done using a resonator in quadrature head (64-channel phase-array antenna). The MRI protocol will take place in two phases:~* Realization of a morphological sequence for the identification of the zone of interest.~* Acquisition of a 1D NMR spectrum in the ventral striatum (right and left).~* Acquisition of a 1D NMR spectrum in the anterior cingulate cortex (right and left).~* Acquisition of a 1D NMR spectrum in the prefrontal cortex (right and left).
Study NCT00862433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha tocopherol
Description: intravenous deuterated vitamin E at doses of 2mg, 5mg, 7.5mg, 10mg and 30mg.
Study NCT00862433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: Deuterated vitamin E, oral and intravenous, at doses of 2mg, 5mg, 7.5mg, 10mg and 30mg.
Study NCT00862433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Oral vitamin C, one gram daily.
Study NCT03604692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axatilimab
Description: axatilimab is a high affinity antibody targeting the colony stimulating factor 1 receptor (CSF-1R). CSF-1R signaling has been demonstrated in nonclinical studies to be the key regulatory pathway involved in the expansion and infiltration of donor derived macrophages that mediate the disease processes involved in cGVHD.
Study NCT01467427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nonacog beta pegol
Description: A single dose of 40 U/kg will be administered intravenously, i.v. (into the vein) once weekly.
Study NCT04144023 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Granulocyte-Macrophage Colony-Stimulating Factor
Description: Given intradermally
Study NCT04144023 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multi-epitope HER2 Peptide Vaccine H2NVAC
Description: Given intradermally
Study NCT04144023 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo standard of care surgery
Study NCT04144023 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT04144023 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT04144023 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT00882895 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell infusion
Study NCT00882895 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TLI
Study NCT00882895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin
Study NCT00882895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solumedrol
Study NCT00882895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Study NCT00882895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Study NCT02240862 — intervention group
Intervention type: DEVICE
Intervention: Carotid Artery Stent
Description: Placement of a stent within the carotid artery
Study NCT01372943 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: synthetic stool or pure cultures of probiotic intestinal bacteria
Description: synthetic stool or pure cultures of probiotic intestinal bacteria from healthy donor stool that can be used as an enema to replace the use of stool transplant, for treatment of recurrent and refractory CDI
Study NCT00788099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plitidepsin and Sorafenib
Description: Patients will receive i.v. plitidepsin over 1h on days 1, 8 and 15 every 4 weeks (d1, 8, 15 q4wk) and continuous oral sorafenib twice daily (bid) (a cycle is defined as an interval of 4 weeks).
Study NCT00788099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Plitidepsin
Description: Patients will receive i.v. gemcitabine over 30 minutes followed 1 hour later by plitidepsin over 1 hour on d1, 8, 15 q4wk (a cycle is defined as an interval of 4 weeks).
Study NCT03621371 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive therapy
Description: Metacognitive therapy is a form av cognitive-behavioral therapy which aims to change cognitions about worry in patients with generalized anxiety disorder.
Study NCT03621371 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intolerance of uncertainty therapy
Description: Intolerance of uncertainty therapy is a form av cognitive-behavioral therapy which aims to reduce cognitive and behavioral avoidance of uncertain situations or cognitions which lead to worry in patients with generalized anxiety disorder.
Study NCT02606422 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active HD-tDCS plus Speech-Language Therapy
Description: Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (inferior frontal gyrus). The stimulation will be delivered at an intensity of 2mA (estimated current density 0.04 mA/cm2; estimated total charge 0.048C/cm2) in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will be oral and written naming.
Study NCT02606422 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham plus Speech-Language Therapy
Description: Speech-language therapy will be administered during sham stimulation. Current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Speech-language therapy will be oral and written naming.
Study NCT02108054 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 7T MRI
Description: Modifying, refining, and verifying the feasibility and applicability of tasks for functional magnetic resonance imaging (fMRI) to measure intended concomitant brain activation
Study NCT03819933 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational intervention
Description: Investigators will first determine preferred language and approaches by families, then redefine current training for prenatal counseling at extreme prematurity by developing and implementing two novel, interdisciplinary simulation-based educational programs for MFM and Neonatology (a workshop and an online module), focusing on eliciting values and building partnerships through advanced communication and relational skills, to improve counseling practices and outcomes
Study NCT02135302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eravacycline
Description: Eravacycline (TP-434) is a parenteral and oral antibiotic of the tetracycline class that is highly active in vitro and in established animal infection models against both nosocomial and community-acquired methicillin-susceptible or -resistant Staphylococcus aureus strains, vancomycin-susceptible or -resistant Enterococcus faecium and Enterococcus faecalis, and penicillin-susceptible or -resistant strains of Streptococcus pneumoniae. In addition, eravacycline is highly active against clinically important species of Enterobacteriaceae (including those isolates that produce extended-spectrum β-lactamases and/or are carbapenem-resistant), Acinetobacter baumannii, and anaerobes.
Study NCT01897480 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2875358
Description: Administered IV
Study NCT01897480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: Administered Orally
Study NCT01897480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Administered Orally
Study NCT04774848 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Frequency Oscillatory Ventilator
Description: HFOV uses a piston diaphragm to generate alternating positive and negative pressure changes to give breaths of 300 to 900/min (5-15 Hz) given over a set mean airway pressure. Both inhalation and exhalation are active.
Study NCT02307396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimozide
Study NCT02307396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perazine
Study NCT02307396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perazine
Study NCT02307396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluphenazine
Study NCT02307396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluphenazine
Study NCT02307396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flupentixole
Study NCT02307396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flupentixole
Study NCT02307396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertindole
Study NCT02307396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertindole
Study NCT03288181 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Muscle Stretch
Description: The splint will be applied to the affected leg as per the protocol for 30 minutes per day, 5 days per week for 4 weeks.
Study NCT03552068 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Treatment (placebo) will be taken during 8 weeks with one visit at 2, 4 and 8 weeks.~Medication: placebo twice a day (in the morning and evening).
Study NCT03552068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: Treatment will be taken during 8 weeks with one visit at 2, 4 and 8 weeks. Medication: 75 μg of clonidine twice a day (in the morning and evening).